Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CCR5 | P51681 | 7/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7793891 | 0.75 | ALDH1A1 (0.38) | ALDH1A1MAPTTSHRFAAHMGLL | |
| SCHEMBL797511 | 0.67 | SCD (0.34) | MEN1KMT2A | |
| SCHEMBL1012468 | 0.66 | SCD (0.37) | MEN1KMT2A | |
| SCHEMBL27496081 | 0.60 | — | — | |
| SCHEMBL29274398 | 0.60 | FAAH (0.68) | ALDH1A1MEN1MAPTKMT2ATSHR | |
| SCHEMBL819092 | 0.60 | FAAH (0.68) | ALDH1A1MEN1MAPTKMT2ATSHR | |
| SCHEMBL1324284 | 0.60 | FAAH (0.68) | ALDH1A1MEN1MAPTKMT2ATSHR | |
| SCHEMBL506356 | 0.60 | FAAH (0.68) | ALDH1A1MEN1MAPTKMT2ATSHR | |
| SCHEMBL25362976 | 0.58 | FAAH (0.74) | MEN1MAPTKMT2ATSHRFAAH | |
| SCHEMBL24218814 | 0.58 | FAAH (0.74) | MEN1MAPTKMT2ATSHRFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328126-B2 | Norbornenylhydrocarbylene dihydrocarbylboranes and methods of making the same | PROMERUS, LLC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2015-12-10 | — | — | US | disclosed |
| WO-2014121008-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | PROMERUS, LLC (US) | 2014-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353582-A1 | NORBORNENYLHYDROCARBYLENE DIHYDROCARBYLBORANES AND METHODS OF MAKING THE SAME | CYP8B1, BDKRB1, CYP1B1 | L3MBTL1 378/4885CCR5 821/4885ALDH1A1 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.